Gene therapy aims to calm overactive bladder for years with one shot
NCT ID NCT07227285
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 16 people who already received EG110A, a gene therapy that uses a modified herpes virus to deliver a botulinum toxin-like protein to relax bladder muscles. Researchers will track side effects and how well the treatment works over five years. The goal is to see if a single injection can safely control overactive bladder caused by spinal cord injury.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EG110A (a gene therapy using a modified herpes virus to deliver botulinum toxin light chain)
What this could lead to
If successful, this could show that a single dose of EG110A safely controls overactive bladder symptoms for years, reducing the need for repeated treatments.
What could go wrong
This is an early-phase, small study (16 people) focused on safety, not proof of effectiveness. Gene therapies can have unexpected long-term side effects, and the virus-based delivery may cause immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPINAL CORD INJURY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Rancho Los Amigos National Rehabilitation Center
Downey, California, 90242, United States
Contact
-
Sidney Kimmel Medical College
Philadelphia, Pennsylvania, 19107, United States
Contact
-
UTHealth Houston / TIRR Memorial Hermann
Houston, Texas, 77030, United States
Contact
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
Contact